Update on the COVID-19 pandemic

Information regarding COVID-19 is in constant change, as is the situation regarding vaccination and prioritization for immune-compromised individuals.

If you have any COVID-19-related questions, we’ve created a specific COVID section on our website that can be accessed by clicking here or by selecting the “News & Events” tab from our homepage. In this section, you’ll find the latest news and information about the pandemic in Canada from trustworthy and reliable sources.

Any specific questions that you may have regarding the COVID-19 vaccination, delays between vaccine dosing, and prioritization within your province are best answered by your healthcare team. They’re the ones who know you and your particular situation and are therefore in a position to best address your unique concerns.

Created by, and entirely focused on, Canadians impacted by myeloma, Myeloma Canada is the only national charitable organization committed to providing you with the most up-to-date and reliable information on myeloma. Some of the ways we do this is through our monthly e-newsletter, “Myeloma Matters”, as well as through our social media platforms.

Please don’t hesitate to contact us at contact@myeloma.ca or toll-free at 1-888-798-5771 with any questions regarding our programs and services.


Make a donation

Prognostic Indicators

A prognosis is a doctor's best estimate of how a disease will affect an individual and how it is likely to respond to treatment.

There are a number of factors that affect the prognosis of a person with multiple myeloma. Some of the most commonly recognized factors are summarized in the chart below. 

Routine laboratory tests Indicators of more active disease 
Beta 2 microblobulin (ß2M) Higher levels
Serum albumin Lower levels
Serum creatinine Higher than normal
Lactate dehydrogenase (LD or LHD) Higher than normal
C-reactive proytein (CRP) Higher than normal
Hemoglobin (red blood cells) Lower than normal
Platelet count Lower than normal
Special tests Indicators of more active disease
Plasma cell labeling index (PCLI) High percentage of plasma cells 
Plasma cell morphology

Presence of immature plasma cells (plasmatic morphology)

Chromosome analysis or FISH (cytogenetic testing)

Absence of chromosome 13 and other cytogenetic abnormalities

Bone marrow microvessel density (MVD) Growth of new blood vessels in the bone marrow

For more information, download the Multiple Myeloma Patient Handbook
Designed to provide educational support to patients, caregivers, families, and friends, this handbook gives accurate, reliable, and clear information on myeloma. Topics cover its causes and effects, how it is diagnosed, and the treatment options available in Canada.
Download it now.